Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes
Relmada Therapeutics was added to the Russell 2000 and Russell 3000 Indexes effective June 26, 2026, following the semi-annual reconstitution. CEO Sergio Traversa highlighted the inclusion as a validation of the company's progress, citing robust 12-month data for NDV-01 in NMIBC and a strong balance sheet.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.